2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-U00122
    Antiulcer Agent 1 76001-09-7
    Antiulcer Agent 1 is a 2-(3,4-dimethoxyphenyl)ethylamine derivative for oral administration at an exploratory stage of new agent development.
    Antiulcer Agent 1
  • HY-U00132
    Embramine 3565-72-8
    Embramine is a monoethanolamine used as an antihistamine and anticholinergic.
    Embramine
  • HY-U00152
    Aminochlorthenoxazin 3567-76-8
    Aminochlorthenoxazin is an antipyretic and analgesic agent.
    Aminochlorthenoxazin
  • HY-U00161
    Betamethasone 17-benzoate 22298-29-9
    Betamethasone 17-benzoate is a representative steroid, which can be used in the treatment of recurrent aphothous ulcers (RAU).
    Betamethasone 17-benzoate
  • HY-U00168
    KP136 76239-32-2
    KP136 (AL136) is an orally effective antiallergic agent. The IC50 is 76.1 μg/mL for histamine release and 63 ug/mL for degranulation.
    KP136
  • HY-U00170
    Bunaprolast 99107-52-5
    Bunaprolast (U66858) is a potent inhibitor of LTB4 production in human whole blood. Bunaprolast (U66858) also exhibits significant inhibition of lipoxygenase and TXB2 release.
    Bunaprolast
  • HY-U00197
    Tilmacoxib 180200-68-4 ≥99.0%
    Tilmacoxib (JTE522) is a highly selective, time-dependent and irreversible human COX-2 inhibitor with an IC50 of 85 nM in an enzyme assay.
    Tilmacoxib
  • HY-U00217
    AZD 4407 166882-70-8
    AZD 4407 is a potent 5-lipoxygenase inhibitor.
    AZD 4407
  • HY-U00222
    S3337 108499-48-5
    S3337 is an H+, K+-ATPase inhibitor.
    S3337
  • HY-U00226
    UP202-56 163838-04-8
    UP202-56 is an adenosine analogue, which is an adenosinergic agonist.
    UP202-56
  • HY-U00235
    SR121566A 180144-61-0
    SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.
    SR121566A
  • HY-U00238
    FRG8701 108498-50-6
    FRG-8701 is a new Histamine H2-receptor antagonist with an IC50 of ranging from 0.25 to 0.43 μM.
    FRG8701
  • HY-U00239
    SC58451 168433-84-9
    SC58451 is a potent and selective Cox-2 inhibitor.
    SC58451
  • HY-U00258
    Minocromil 85118-44-1
    Minocromil (FPL59360) is a new Anti-asthmatic agent.
    Minocromil
  • HY-U00260
    CMI977 175212-04-1
    CMI977 is a potent 5-Lipoxygenase (5-LO) inhibitor.
    CMI977
  • HY-U00261
    L-689502 138483-63-3
    L-689502 is a potent inhibitor of HIV-l protease with an IC50 of 1 nM.
    L-689502
  • HY-U00263
    LY210073 148291-65-0
    LY210073 is a Leukotriene B4 (LTB4) receptor antagonist with an IC50 of 6.2 nM.
    LY210073
  • HY-U00273
    Anti-inflammatory agent 1 1096621-42-9
    Anti-inflammatory agent 1 is an anti-inflammatory agent extracted from patent WO 2009003229 A1, example 36.
    Anti-inflammatory agent 1
  • HY-U00278
    Deloxolone 68635-50-7
    Deloxolone has the potential for inflammatory, ischemic and proliferative diseases treatment.
    Deloxolone
  • HY-U00282
    Chymase-IN-2 936366-22-2
    Chymase-IN-2 is a chymase modulator which is useful in the treatment of inflammatory and serine protease mediated disorders.
    Chymase-IN-2
Cat. No. Product Name / Synonyms Application Reactivity